Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients

Summary

Treating Gastric Cancer and Esophagogastric junction adenocarcinoma Patients with MET gene amplifications with Savolitinib

Timeline

Start

2021-07-27

Primary completion

2026-04-21

Completion

2026-04-21

Outcome

Met primary endpoint

paper Independent review committee-assessed ORR was 32.3% (95% confidence interval 21.2-45.1%) in the pivotal phase, which met the predefined efficacy threshold PMID 42225990 ↗

Publications

• Peng Z, Liu T, Wang H, Wang J, Liu H, Ye F, Li E, Zhang J, Liu B, Lin R, Zhou A, Liu Z, Xu H, Wang Q, Niu Z, Yuan Y, Qin Y, Qu X, Bai Y, Liu N, Liu H, Bai C, Pan Y, Wang S, Wu T, Pan Q, Zhong D, Lu H, Wang J, Wang Z, Deng T, Gou H, Huang X, Fu S, Lu P, Yu J, Hong M, Xu Q, Wang L, Ren Y, Fan S, Shen L; Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma study group. Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. Nat Med. 2026 Jun 1. doi: 10.1038/s41591-026-04459-7. Online ahead of print.

Drugs

Indications